Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

  • Imam, Farhad
  • Anastasi, Federica
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
  • Global Neurodegeneration Proteomics Consortium (GNPC)
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research., We thank all GNPC V1 consortium members who helped support the creation of the V1 harmonized dataset. We thank the participants, their families as well as the cohorts, institutions and their dedicated staff who helped create this consortium. Funding for the majority of biosample analyses was provided by Gates Ventures and Johnson & Johnson. Funding for cohort creation, participant biosample collection and additional biosample analysis was provided by the following sources. ALLFTD data collection and dissemination was supported by the ALLFTD Consortium (U19: AG063911, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by NINDS and the National Center for Advancing Translational Sciences; LEFFTDS: U01 AG045390, funded by the NIA and the NINDS). Additional funding support was provided by the National Institutes of Health (NIH)-NIA for Frontotemporal Dementia: Genes, Images, and Emotions: P01 AG019724 and the UCSF Alzheimer’s Disease Research Center: P30 AG062422. Samples from the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the NIA, were used in this study. The ALLFTD proteomic data included in this paper were funded by a grant from Gates Ventures. Alzheimer and Families (ALFA) was supported by funding from the MCIN/AEI/10.13039/501100011033/FEDER, European Union, through the PID2023-153312OB-I00 project; the CaixaResearch Institute under the project titled DETEC-PK; and the RYC2023-043831-I grant, funded by MCIN/AEI/10.13039/501100011033 and the FSE+. Additional researchers receive funding from the JDC2022-049347-I grant, funded by MCIU/AEI/10.13039/501100011033, the European Union NextGenerationEU/PRTR, the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER), the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project SLD077/21/000001, Project ‘PI19/00155’ and ‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). The ALFA proteomic data included in this paper were funded by a grant from Gates Ventures. Stichting Alzheimer Nederland and Stichting VUmc provided funds for supporting Alzheimer Center Amsterdam infrastructure. Additionally, ZonMw Memorabel program project ‘PRODIA’, as part of the Deltaplan Dementie, and 2bike4alzheimer (Alzheimer Nederland) are acknowledged for funding this study for the generation of proteomics data for Amsterdam UMC. The baseline ABC-PD study (study period 2014–2017) was funded by a pre-competitive grant from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. The follow-up study (study period 2018–2020) was funded by a grant from the Michael J. Fox Foundation for Parkinson’s Research (grant no. 15227). Neither study sponsor was involved in collection, analysis and interpretation of data, writing of the report or decision to submit the manuscript for publication. Janssen Research and Development was only involved in study design of the baseline visit. Answer ALS was supported by NEALS Biofluid Repository, and Answer ALS collected, annotated and granted permission to use ALS biofluid samples. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Baltimore Longitudinal Study of Aging (BLSA) was supported by the Intramural Research Program (IRP) of the NIH-NIA. Banner Health was supported by Arizona ADRC and Arizona APOE grants from the NIA (P30 AG019610 and R01 AG069453), the state of Arizona, the Banner Alzheimer’s Foundation, the Sun Health Foundation, the Michael J. Fox Foundation and Gates Ventures. Work at Lund University was supported by the NIA (R01AG083740), the ERC (ADG-101096455), the Alzheimer’s Association (ZEN24-1069572 and SG-23-1061717), the GHR Foundation, the Swedish Research Council (2022-00775 and 2021-02219), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907 and AF-994229), the Swedish Brain Foundation (FO2021-0293 and FO2023-0163), the Parkinson Foundation of Sweden (1412/22), the Cure Alzheimer’s Fund, the Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), the WASP and DDLS joint call for research projects (WASP/DDLS22-066), the Lilly Research Award Program, Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080 and 2022-Projekt0107). Additionally, this work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant no. KAW 2020.0239), the Swedish Research Council (2024-03642), the NIA (U01 AG079847-02) and Gates Ventures. The CHARIOT-PRO study was funded by Johnson & Johnson, Merck, Takeda and Gates Ventures, and analysis was supported by the UKRI Future Leaders Fellowship (MR/S03532X/1 and MR/Y02012X/1) and the NIHR ARC Dementia Fellowship. The Emory ADRC participation was supported by the Emory Goizueta Alzheimer’s Research Disease Center (P50AG025688) and grants from Gates Ventures for the generation of proteomics data, and data collection was supported through funding by NIA grants R01AG053960, R01AG057911, R01AG061800, RF1AG057471, RF1AG057470, R01AG061800, R01AG057911 and R01AG057339. The Kansas ADRC participation was supported by the NIH (P30 AG072973, P30 AG072974 and R01 AG064227) and further supported by the Neil & Norma Hill Foundation, the Annemarie & Arturo Gandioli-Fumagalli Foundation, the Perpetual Foundation, the John Williams Endowment and the Hillcrest Foundation. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Knight ADRC participation was supported by grants from the NIH (R01AG044546, RF1AG053303, RF1AG058501 and U01AG058922), the Michael J. Fox Foundation, the Alzheimer’s Association Zenith Fellows Award (ZEN-22-848604), Gates Ventures and an anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, P01AG03991 and P01AG026276. Additionally, this work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The Whitehall II study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (Y014154, R024227, S011676 and K013351) and the NIA (R01AG056477 and R01AG062553).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease

  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, setting, and participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main outcome and measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments., Work at the authors’ research center (Lund University) was supported by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775 and 2018-02052, 2021-02219), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-994229), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer’s Fund, Rönström Family Foundation, Berg Family Foundation, Greta och Johan Kock Foundation, WASP and DDLS joint call for research projects (WASP/DDLS22-066), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), Bundy Academy at Lund University (2025-2026-2024-2428) and the Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). Dr Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie action grant agreement number 101061836, an Alzheimer’s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University. This study was also funded by the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects INT21/00073, PI20/01473 and PI23/01786 to Dr Fortea) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund. This work was also supported by National Institutes of Health grants R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to Dr Fortea. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to Dr Fortea) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to Dr Fortea). Dr Suárez-Calvet received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III and cofunded by the European Union; and from a fellowship from la Caixa Foundation (100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). The Translational Biomarkers in Aging and Dementia cohort is supported by the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815 and 162303), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31-team 1), the Alzheimer’s Association (NIRG-12-92090 and NIRP-12-259245), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314) and the Colin J. Adair Charitable Foundation. The Wisconsin Registry for Alzheimer's Prevention cohort was supported by R01AG027161, R01AG021155 and P30AG062715 from SC Johnson. The Australian Imaging Biomarkers and Lifestyle Study of Ageing study is funded by the Commonwealth Scientific and Industrial Research Organization, and the National Health and Medical Research Council. The Sant Pau Initiative on Neurodegeneration cohort received funding from the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI19/00882, PI18/00435, PI22/00611, INT19/00016, INT23/00048, PI17/01896, and AC19/00103), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas program, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. The Sant Pau Initiative on Neurodegeneration cohort was also supported by the National Institutes of Health (grants 1R01AG056850-01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408), Marató TV3 Foundation grants 20141210, 044412 and 20142610, a grant from the Fundació Bancaria La Caixa (Down Alzheimer Barcelona Neuroimaging Initiative project), Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas. Horizon 21 Consortium is partly funded by Jérôme Lejeune Foundation. PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Québec–Santé, an unrestricted research grant from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Additional funding sources include the Canadian Institutes of Health Research (438655), US National Institutes of Health (R01 AG068563), Alzheimer’s Association, Alzheimer Society of Canada and Brain Canada grants. Dr Blennow is supported by the Swedish Research Council (2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (AF-930351, AF-939721, AF-968270, and AF-994551), Hjärnfonden, Sweden (ALZ2022-0006 and FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer, the Kirsten and Freddy Johansen Foundation, and Familjen Rönströms Stiftelse. Dr Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, cofinanced from the European Union’s Horizon Europe Research and Innovation Programme and by the participating states (22HLT07 NEuroBioStand). The CANTATE project was funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council, Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation, and Alzheimer Netherlands. Dr Teunissen is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (LSHM20106), and of TAP-dementia, a ZonMw-funded project (10510032120003) in the context of the Dutch National Dementia Strategy.